Nigerian fintech Appzone raises $10M for expansion and proprietary technology
23 Apr, 2021
– Cybrexa Therapeutics from New Haven develops a new class of therapeutics through its alphalex™ Peptide Drug Conjugate (PDC) tumor targeting platform.
– The company completed its $25m Series B financing.
– Backers included HighCape Capital and new investor Elm Street Ventures.
– The new investment will be aimed at planned advancement of its lead candidate CBX-12 (alphalex™-exatecan) into the clinic.